Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Two-thirds of reviewers reported losing weight, suppressing appetite, or eliminating food cravings
Fifth, cost-effectiveness analyses are critical given the high price of current GLP-1 RAs and the large potential treatment population: preliminary health-economic models suggest acceptable cost-effectiveness ratios in high-fibrosis patients with comorbid type 2 diabetes and cardiovascular disease, but robust data in broader MASLD populations are lacking
Weight regain after stopping is common and reflects the return of pre-treatment appetite signals rather than a personal shortcoming
Lack of Data on Human Pregnancies One of the biggest concerns about using tirzepatide during pregnancy is that there is very little data available on its effects
US$ 21.67
US$ 22.95
US$ 21.40
US$ 22.40
